Gemcitabine monotherapy in recurrent ovarian cancer: from the bench to the clinic
Author:
- 1 May 2005
- journal article
- review article
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 15 (s1) , 12-17
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Detection of an alternatively spliced form of deoxycytidine kinase mRNA in the 2′-2′-difluorodeoxycytidine (gemcitabine)-resistant human ovarian cancer cell line AG6000Biochemical Pharmacology, 2004
- Gemcitabine-induced radiation recall dermatitis following whole pelvic radiation therapyGynecologic Oncology, 2003
- Randomized Phase II Comparison of Dose-Intense Gemcitabine: Thirty-Minute Infusion and Fixed Dose Rate Infusion in Patients With Pancreatic AdenocarcinomaJournal of Clinical Oncology, 2003
- Cell cycle effects of gemcitabineInternational Journal of Cancer, 2001
- Molecular Identification and Characterization of Novel Human and Mouse Concentrative Na+-Nucleoside Cotransporter Proteins (hCNT3 and mCNT3) Broadly Selective for Purine and Pyrimidine Nucleosides (System cib)Journal of Biological Chemistry, 2001
- Decreased resistance to gemcitabine (2′,2′-difluorodeoxycitidine) of cytosine arabinoside-resistant myeloblastic murine and rat leukemia cell lines: role of altered activity and substrate specificity of deoxycytidine kinaseBiochemical Pharmacology, 1999
- Activity of Gemcitabine in Patients with Advanced Ovarian Cancer: Responses Seen Following Platinum and PaclitaxelGynecologic Oncology, 1996
- Phase II Study of Gemcitabine (2',2'-Difluorodeoxycytidine) in Previously Treated Ovarian Cancer PatientsJNCI: Journal of the National Cancer Institute, 1994
- 2′,2′-Difluoro-deoxycytidine (gemcitabine) incorporation into RNA and DNA of tumour cell linesBiochemical Pharmacology, 1993
- Modulation of deoxycytidylate deaminase in intact human leukemia cellsBiochemical Pharmacology, 1992